Case report

Central retinal vein occlusion: a case report and review of the literature
Tarek Alasil*, Nahyoung Lee, Pearse Keane and Srinivas Sadda

Address: Doheny Eye Institute, University of Southern California, Los Angeles, CA 90033, USA
Email: TA* - tarekalasil@hotmail.com; NGL - nahyoung.lee@gmail.com; PK - pkeane@doheny.org; SRS - ssadda@doheny.org
* Corresponding author

Published: 3 June 2009
Received: 14 April 2009
Accepted: 16 May 2009

Cases Journal 2009, 2:7170 doi: 10.1186/1757-1626-2-7170
This article is available from: http://casesjournal.com/casesjournal/article/view/7170

© 2009 Alasil et al; licensee Cases Network Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction: Central retinal vein occlusion is one of the major causes of severe vision impairment and blindness in adults.

Case presentation: We present a case of unilateral ischemic central retinal vein occlusion in a 54-year-old woman with history of uncontrolled hypertension and open angle glaucoma. Laboratory tests including complete hypercoagulability and thrombotic workup were completed.

Conclusion: Our case illustrates an interesting presentation of unilateral ischemic central retinal vein occlusion, where hypertension and glaucoma were thought to be the main risk factors. Close follow up, tight blood pressure and glaucoma control are crucial to prevent similar scenario in the fellow eye.

Introduction

Central retinal vein occlusion (CRVO) is one of the major causes of severe vision impairment and blindness [1].

Thrombosis of the central retinal vein results in venous stasis, leading to disc swelling, diffuse nerve fiber layer and pre-retinal hemorrhage, and cotton wool spots that create a dramatic appearance, often called "the blood and thunder" fundus.

The prevalence of central retinal vein occlusion (CRVO) is 0.1 to 0.7 percent in population-based studies [2]. A population-based study found a cumulative incidence of 0.5 percent over 15 years, with a prevalence of 1.3 percent for people aged 65 years and older [3].

Occlusion or thrombosis of the central retinal vein is associated with chronic glaucoma, atherosclerotic risk factors (age, diabetes, and hypertension), hyperviscosity, coagulopathy, and migraine [3-6]. The cause of retinal vein occlusion is often unknown.

While vision loss may be severe, the onset is typically subacute, in contrast to the sudden visual loss typical of central retinal artery occlusion. When venous stasis is severe, infarction may occur due to slowed retinal blood flow on the arterial side. In this setting, a relative afferent papillary defect is often present.

We present an interesting case of unilateral ischemic central retinal vein occlusion. We will discuss the risk factors in detail and review the literature.
factors, the complications, and the management guidelines in CRVO.

**Case presentation**

A 54-year-old African American female with history of uncontrolled hypertension and glaucoma presented to the eye clinic with sudden vision loss in the right eye upon awakening. She has been taking Clonidine 10 mg oral twice daily and Latanoprost 1 drop in each eye twice daily.

Vital signs upon presentation are summarized in Table 1. Electrocardiogram showed sinus rhythm, and left ventricular hypertrophy.

Ophthalmologic exam showed best corrected visual acuity of hand motion in the right eye and 20/70 in the left eye. Pupil exam showed sluggish right pupil with relative afferent papillary defect, and a reactive pupil on the left.

Intraocular pressures were 19 mmHg in the right, and 11 mmHg in the left.

Slit lamp exam showed normal anterior segments with open angles bilaterally.

Fundus examination of the right eye revealed cup to disk ratio of 0.7, dilated and tortuous retinal veins, with intraretinal hemorrhages especially in the peripapillary region (Figure 1). Fundus examination of the left eye revealed cup to disk ratio of 0.7, otherwise normal optic disc and flat macula.

Differential diagnosis in the right eye included central retinal vein occlusion (CRVO), ocular ischemic syndrome, diabetic retinopathy, papilledema, and acute hypertensive retinopathy (Figure 3).

Flourescein Angiogram of the right eye showed blocked venous fluorescence from the retinal hemorrhages, extensive areas of capillary non-perfusion, and vessel wall staining. Patient was diagnosed with unilateral ischemic central retinal vein occlusion in the right eye. Laboratory tests including complete hypercoagulability and thrombotic workup were completed (Tables 2, 3).

Patient was prescribed aspirin 81 mg daily. Amlodipine 10 mg, and Hydrochlorothiazide 25 mg were added to achieve better blood pressure control. Timolol and Brimonide eye drops were added to achieve better control of the intraocular pressure.

Patient was advised to follow closely during the next six months, including gonioscopy and undilated examination of the iris to check for neovascularization of the iris/disc.

**Table 1.** Vital signs upon presentation are summarized in Table 1

|          |          |
|----------|----------|
| Temperature | 97.0 F   |
| Respiratory rate | 19 breath/min |
| Blood pressure | 190/103 mmHg |
| Heart rate | 64 bpm   |
| Pain      | 0/10     |

**Figure 1.** Color Fundus photograph of the right eye showed superficial opacification of the retina in the macular area in combination with multiple dot-blot and flame-shaped hemorrhages in all four quadrants (including the area nasally to the optic nerve).

**Figure 2.** Color Fundus photograph of the left eye showed normal optic disc, and flat macula (normal findings).
Discussion

CRVO has two types:

- Nonischemic (70%): which is characterized by vision that is better than 20/200, 16% progress to nonperfused; 50% resolve completely without treatment; defined as <10 disk diameter (DD) of capillary nonperfusion.

- Ischemic (30%): which is defined as more than 10 DD of nonperfusion; patients are usually older and have worse vision; 60% develop iris NV; up to 33% develop neovascular glaucoma; 10% are combined with branch retinal arterial occlusion (usually cilioretinal artery due to low perfusion pressure of choroidal system) [7].

Central retinal vein occlusion is a disease of the old population (age >50 years old). Major risk factors are hypertension, diabetes, and atherosclerosis. Other risk factors are glaucoma, syphilis, sarcoidosis, vasculitis, increased intraorbital or intraocular pressure, hyphema, hyperviscosity syndromes (multiple myeloma, Waldenstrom’s macroglobulinemia, and leukemia), high homocysteine levels, sickle cell, and HIV [8].

Paul O’Mahoney et al. studied the relationship between traditional atherosclerosis risk factors and retinal vein occlusion (RVO). They systematically retrieved all studies between 1985 and 2007 that compared cases with any RVO with controls. They concluded that hypertension and hyperlipidemia are common risk factors for RVO in adults, and diabetes mellitus is less so. It remains to be determined whether lowering blood pressure and/or serum lipids levels can improve visual acuity or the complications of RVO [9].

Open-angle glaucoma is the most common local factor predisposing to RVO as increased intraocular pressure compromises retinal vein outflow and produces stasis [10,11].

Central retinal vein occlusion is a disease of the old population (age >50 years old). Major risk factors

Table 2. Laboratory tests including hypercoagulability workup are summarized in Table 2

| Test                          | Result          |
|-------------------------------|-----------------|
| Glucose                       | 90              |
| HgA1c                         | 5.8             |
| White blood cell count        | 9.8             |
| Neutrophils                   | 80%             |
| Lymphocytes                   | 14%             |
| Monocytes                     | 4.6%            |
| Hemoglobin                    | 15.0            |
| Hematocrit                    | 45.1            |
| Platelets                     | 282             |
| MCV                           | 84.3            |
| RDW                           | 14.6            |
| Prothrombin time              | 12.5            |
| INR                           | 0.99            |
| PTT LA                        | 33 normal (Reference normal < 40) |
| ANA                           | Negative        |
| Rheumatoid factor             | Negative        |
| ESR                           | 10 (normal)     |
| CRP                           | 20 (normal)     |
| Serum protein electrophoresis | Normal          |
| Lipid profile                 | Normal          |
| Hemoglobin electrophoresis    | Normal          |
| VDRL                          | Negative        |
| FTA-ABS                       | Negative        |

Table 3. Further hypercoagulability workup is summarized in Table 3

| Test                                      | Result          |
|-------------------------------------------|-----------------|
| HIV                                       | Negative        |
| Functional protein S assay                | Normal          |
| Functional protein C assay                | Normal          |
| Functional antithrombin III assay         | Normal          |
| Antiphospholipid antibody titer           | 262 (reference range = 151-264) |
| Lupus anticoagulant                       | Negative        |
| Anticardiolipin antibody                  | Negative        |
| Homocysteine                              | 11.5 (0-10)     |
| Folate level                              | Normal          |
| B12 level                                 | Normal          |
| Creatinine                                | 0.9 mg per deciliter |
| Factor V Leiden PCR assay                 | Negative        |
Every eye with CRVO is at risk for developing neovascular glaucoma. Lowering intraocular pressure helps to improve retinal circulation in an eye with CRVO [12], and there is a 10% risk for development of BRVO or CRVO in the fellow eye [13].

Risk factors for developing neovascular iris in patients with CRVO are the amount of nonperfused retina, extent of retinal hemorrhages, male sex, and central vein occlusion of less than one month duration [14]. Visual acuity in patients with CRVO at baseline is a strong predictor for the development of INV/ANV, as is the amount of nonperfusion seen by fluorescein angiogram [1].

The central vein occlusion study (CVOS) data did not support the recommendation for prophylactic panretinal photocoagulation (PRP). The CVOS found that early PRP decreased the rate of iris neovascularization (INV); however, the reduction was not statistically significant. Moreover, the study showed that early PRP reduced, but did not eliminate, the possibility of anterior-segment neovascularization. The CVOS recommended close follow-up of eyes with CRVO during the first 6 months (including gonioscopy and undilated slit lamp examination of the iris) and prompt PRP of eyes in which iris neovascularization (INV)/Angle neovascularization (ANV) develops [14].

Although PRP was better than selective PRP or photodynamic therapy (PDT) at determining INV and anterior-segment neovascularization regression, selective PRP or PDT can also be safely used to manage anterior-segment neovascularization secondary to ischemic CRVO [15].

Conclusion
Our case illustrates an interesting presentation of unilateral ischemic central retinal vein occlusion, where hypertension and glaucoma were thought to be the main risk factors. While many interventions for fixed visual loss associated with CRVO have largely not proven to be of benefit, our management focused on controlling blood pressure and glaucoma as preventive measures to protect the fellow eye. Meanwhile, close follow up was emphasized to investigate for signs of iris/angle neovascularization.

List of abbreviations
CRVO, Central retinal vein occlusion; CVOS, Central vein occlusion study; PRP, Panretinal photocoagulation; INV, Iris neovascularization; ANV, Angle neovascularization; PDT, Photodynamic therapy.

Consent
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
TA analyzed and interpreted the patient data, and wrote the manuscript. NGL examined the patient in the clinic, and helped with collecting the data. PK helped with the differential diagnosis, and contributed in writing the manuscript. SRS was the retina attending who staffed and reviewed the case. All authors read and approved the final manuscript.

References
1. The Central Vein Occlusion Study Group: Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997, 115:486-491.
2. Mohamed Q, McIntosh RL, Saw SM, Wong, TY: Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007, 114:507.
3. Klein R, Moss SE, Meuer SM, Klein BE: The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 2008, 126:513.
4. Frisco D, Marcucci R: Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 2002, 32:308.
5. Cugati S, Wang JJ, Knudtson MD et al.: Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology 2007, 114:520.
6. Bioussé V, Newman NJ, Sternberg P Jr: Central retinal vein occlusion and transient monocular visual loss associated with hyperhomocystinemia. Am J Ophthalmol 1997, 124:257.
7. Freundman N, Kaiser P, Trattler W: Central retinal vein occlusion. Review of ophthalmology 2005, Chapter 11:329.
8. Bhagat N, Goldberg MF et al.: Central retinal vein occlusion: review of management. Eur J Ophthalmol 1999, 9:165-180.
9. Paul R. A ‘O’Maloney, David T. Wang et al.: Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol 2008, 126:692-699.
10. Rath EZ, Frank RN, Shin DH, Kim C: Risk factors for retinal vein occlusions. A case-Control Study Group. Ophthalmology 1992, 99:509-514.
11. Anon: Risk factors for central retinal vein occlusion. The eye disease Case-Control Study Group. Arch Ophthalmol 1996, 114:545-554.
12. Hayreh SS: Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005, 24:493-519.
13. Central Vein Occlusion Study Group: Baseline and early natural history report. The Central Vein Occlusion Study. Arch Ophthalmol 1993, 111:1087.
14. The Central Vein Occlusion Study Group: A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The central vein occlusion study group N report. Ophthalmology 1995, 102:1434-1444.
15. Porodí, Maurizio Battaglia et al.: Panretinal photocoagulation and photodynamic therapy for anterior segment neovascularization secondary to ischemic central retinal vein occlusion. Ophthalmic surgery, Laser and Imaging 2007, 38:94-99.